Tenamfetamine

The MDA's 2025 Clinical & Scientific Conference will focus on latest advancements in neuromuscular medicine, including genetic therapies, AI in clinical settings, and muscle regeneration. The event aims to educate clinicians, foster multidisciplinary collaboration, and accelerate progress in treating neuromuscular disorders.

Scholar Rock announced successful Phase 3 SAPPHIRE study results for apitegromab in treating SMA, showing significant motor function improvement. Plans include filing regulatory applications in Q1 2025 and a U.S. commercial launch in Q4 2025. The company raised $345 million, boosting its cash balance to $463 million, and is preparing for apitegromab's potential $1 billion revenue.

S.P. reports research grants and consulting fees from various pharmaceutical companies and organizations. M.C. reports consulting fees and institutional research support from multiple entities and serves on the board of Praxis. B.H. and E.G. report no competing interests.

Postbiotic supplementation in CVA patients improved inflammatory factors, oxidative stress markers, and SOFA scores, reduced pneumonia incidence, and increased TAC levels, indicating potential benefits in inflammation and oxidative stress reduction.